Comparative Pharmacology
Head-to-head clinical analysis: DORIBAX versus MEROPENEM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DORIBAX versus MEROPENEM.
DORIBAX vs MEROPENEM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Doripenem is a carbapenem antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It has broad-spectrum activity against Gram-positive, Gram-negative, and anaerobic bacteria.
Meropenem inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP 2 and PBP 3, leading to cell death.
1 g IV every 8 hours over 1 hour for complicated intra-abdominal infections, complicated urinary tract infections (including pyelonephritis), and hospital-acquired pneumonia (including ventilator-associated pneumonia).
1-2 g IV every 8 hours, infused over 15-30 minutes; typical dose 1 g q8h for complicated infections. Extended infusion over 3 hours may be used for resistant organisms.
None Documented
None Documented
Clinical Note
moderateMeropenem + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Meropenem."
Clinical Note
moderateMeropenem + Valproic acid
"The serum concentration of Valproic acid can be decreased when it is combined with Meropenem."
Clinical Note
moderateMeropenem + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Meropenem."
Terminal elimination half-life approximately 1 hour in healthy adults; prolonged to ~4 hours in renal impairment (CrCl <30 mL/min).
1.0-1.5 hours in adults with normal renal function; prolonged to 4-6 hours in moderate renal impairment (CrCl 10-50 mL/min) and up to 7-10 hours in severe renal impairment (CrCl <10 mL/min).
Renal: approximately 70-75% unchanged in urine; biliary/fecal: minimal (less than 20% total, primarily as metabolite).
Renal: 70% unchanged via glomerular filtration and tubular secretion. Biliary: <2% excreted in bile. Fecal: ~2%.
Category C
Category A/B
Carbapenem Antibiotic
Carbapenem Antibiotic